In another study, it was shown that the combination of LSD1 inhibitor and anti-PD-1 antibody was especially effective in xenograft NSCLC tumors with lower expression of Trim35—an E3 ligase which causes LSD1 ubiquitination and inactivation [160]. The gene discussed is KDM1A; the disease is non-small cell lung carcinoma.